Zydus Lifesciences Limited (ZYDUSLIFE)
Investor Presentation
AI summary
- Total revenues grew 22% YoY to Rs. 80,170 mn in Q1 FY27
- India branded formulations outpaced market with 20% YoY growth
- North America formulations grew sequentially with volume expansion and 11 new product launches
- International Markets sustained strong growth with 34% YoY increase
- EBITDA margin declined 770 bps YoY to 24.1%
- Capex for the quarter was Rs. 5,852 mn; Net Debt stood at Rs. 59,041 mn
- USFDA granted priority review for Saroglitazar Magnesium NDA; Phase III trials initiated for Desidustat
- Consumer Wellness domestic business grew 5% YoY; international business grew 25% YoY
- MedTech business enhanced capabilities in focused therapies
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 ZYDUSLIFE — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add ZYDUSLIFE to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Zydus Lifesciences Limited
Important.
The summary above is generated automatically from Zydus Lifesciences Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.